AROMICS develops a novel therapy for malignant mesothelioma

AROMICS is developing a novel therapy for the treatment of rare and highly refractory cancers like malignant mesothelioma, an asbestos-related cancer.

European Commission through its SME instrument at Horizon 2020 program is supporting the company in the development.